Variables | Migraineurs with CA (n = 43) | Migraineurs without CA (n = 37) | p-value a |
---|---|---|---|
Age (years) | 41 ± 11 | 37 ± 9 | 0.05 |
Female (%) | 86.5% | 75.7% | 0.24 |
Height (m) | 1.64 ± 0.09 | 1.65 ± 0.08 | 0.52 |
Weight (kg) | 64.7 ± 11.2 | 64.1 ± 12.4 | 0.79 |
BMI (kg/m2) | 24.1 ± 3.9 | 23.4 ± 3.1 | 0.42 |
Body composition – ViScan abdominal fat | 35.7 ± 8.7 | 32.9 ± 7.5 | 0.04 |
Body fat percentage | 32.6 ± 9.4 | 31.1 ± 7.78 | 0.07 |
HIT-6 | 62.68 ± 7.19 | 58.47 ± 9.03 | 0.03 |
MIDAS | 54.83 ± 57.83 | 29.03 ± 40.09 | 0.05 |
Migraine evolution (years) | 9.9 ± 8.6 | 9.7 ± 10.3 | 0.03 |
Frequency (attacks per month) | 9.49 ± 8.70 | 5.25 ± 5.17 | 0.23 |
1–9 days per month | 23 (53.5%) | 28 (75.0%) | |
10–14 days per month | 1 (2.3%) | 1 (2.8%) | 0.31 b |
> 15 days per month | 19 (44.2%) | 8 (22.2%) | |
Analgesic consumption (last month) | 11.32 ± 8.01 | 7.36 ± 7.39 | 0.03 |
Triptan consumption (last month) | 4.47 ± 6.69 | 3.05 ± 6.51 | 0.464 |
Medication overuse | 21 (48.8%) | 10 (27.0%) | 0.726 b |
Use of migraine prophylaxis | 25 (59.5%) | 12 (32.4%) | 0.02 b |
Depression (%) | 16.2% | 10.8% | 0.49 b |
Anxiety disorders (%) | 37.2% | 37.5% | 0.95 b |
Sleep disorders (%) | 69.8% | 43.2% | 0.02 b |